Meitav Investment House’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Meitav Investment House’s Portfolio CANF Stock Details CANF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-170	Closed	-$103K	–	446
2019 Q2	$103K	Hold	170	–	–	0.01%	417
2019 Q1	$448K	Buy	170 +14	+9%	+$48.9K	0.03%	255
2018 Q4	$518K	Buy	156 +33	+27%	+$127K	0.03%	198
2018 Q3	$488K	Buy	+123	New	+$461K	0.02%	322
2018 Q2	–	Sell	-81	Closed	-$352K	–	429
2018 Q1	$352K	Buy	81 +29	+56%	+$160K	0.02%	276
2017 Q4	$240K	Buy	+52	New	+$238K	0.01%	186

Other funds holding CANF

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Meitav Investment House's CANF Position: Q3 2019 in Review

Meitav Investment House sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q3 2019, closing a stake of 170 shares — an estimated $103K sold.

Meitav Investment House first reported a position in CANF in Q4 2017 and held it in 6 quarters. The position peaked at $518K in Q4 2018. 5 funds tracked by Wall St. Rank hold CANF as of Q3 2019.

Meitav Investment House reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q3 2019 after selling out during the quarter.
Meitav Investment House sold 170 Can-Fite BioPharma American Depositary Shares shares in Q3 2019, an estimated $103K.
Meitav Investment House first reported a position in Can-Fite BioPharma American Depositary Shares in Q4 2017 and held it in 6 quarters.
Meitav Investment House's Can-Fite BioPharma American Depositary Shares position peaked at $518K in Q4 2018.
5 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q3 2019.

Based on Meitav Investment House's 13F filing for Q3 2019, filed 14 Nov 2019.